Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
This research aims to better understand Congenital Myasthenic Syndromes CMS caused by mutations in the genes DOK7, MUSK, AGRN, or LRP4. It focuses on evaluating disease activity by collecting clinical assessments to study symptoms and quality of life in affected participants. The study is observational and seeks to gather detailed information about the natural history of CMS over time. Participants will attend up to four study visits where clinical assessments will be performed. These visits will collect data on participants symptoms and health status related to CMS, including scores like the Quantitative Myasthenia Gravis QMG and other quality of life measures. The study does not involve treatment but focuses on monitoring and documenting disease progression and healthcare utilization. During the study, researchers will collect and review data such as diagnosis details, medication use, healthcare visits, and changes in health status over a period of up to 12 months. Participants will undergo assessments including clinical evaluations and questionnaires to measure fatigue, daily activities, and general health. This information will help to provide summary statistics about CMS and support understanding of this conditions impact on patients.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of JNJ-78934804 compared to guselkumab in adults with moderately to severely active Crohns disease, a long-term and progressive intestinal condition. This Phase 3 study aims to assess how well these treatments work by measuring clinical and endoscopic remission at Week 48. The study is sponsored by Janssen Research & Development, LLC. Participants are randomly assigned to receive either JNJ-78934804 or guselkumab, both given as subcutaneous injections. Treatment starts with induction doses at Weeks 0, 4, and 8, followed by maintenance doses every 4 weeks from Week 12 onward. Those meeting rescue criteria during the study may receive additional induction doses of JNJ-78934804 at Weeks 16, 20, and 24, then continue maintenance dosing from Week 28. After completing the double-blind phase at Week 48, participants who may benefit can join a long-term extension phase. During the study, participants will undergo assessments to measure clinical remission, endoscopic remission, and other outcomes like deep remission and corticosteroid-free remission at various time points. Researchers will monitor patient-reported outcomes, adverse events, and serious adverse events for up to approximately three years. The study involves regular evaluations of disease activity and safety to understand treatment effects and participant well-being over time.
Actively Recruiting
Researchers are evaluating BOLD-100, an intravenous ruthenium-based small molecule drug, in combination with FOLFOX chemotherapy with or without Bevacizumab for treating advanced gastrointestinal cancers such as colorectal, pancreatic, gastric cancers, and cholangiocarcinoma. This Phase 1b2a non-randomized study includes a dose escalation phase to assess safety and tolerability, followed by a cohort expansion phase focusing on patients with advanced solid tumors. The study aims to understand BOLD-100s potential when combined with standard chemotherapy regimens. Participants receive BOLD-100 combined with FOLFOX chemotherapy, with or without Bevacizumab, in different dose levels including 500 mgm2 and 625 mgm2. The study includes multiple arms, some closed to enrollment and others open to patients with colorectal cancer who are oxaliplatin naive and have had only one prior metastatic treatment. Participants are randomized in Arm VII to receive one of two doses of BOLD-100 plus FOLFOX Bevacizumab or FOLFOX Bevacizumab alone. Throughout the study, participants undergo assessments for adverse events, dose-limiting toxicities, physical exams, ECGs, laboratory tests, and performance status. Quality of life questionnaires focusing on general and neuropathy-related aspects are completed by those in Arm VII. Researchers measure progression-free survival, overall response rate, and overall survival. The study also monitors pharmacokinetics and biomarkers during treatment. Participation continues until approximately two weeks after the last treatment, with ongoing safety and efficacy evaluations.
Actively Recruiting
Researchers are conducting an observational, multicenter, international study to learn about antimicrobial resistance AMR in people with chronic lung diseases CLD worldwide. The study aims to understand how common AMR is in these patients, how it varies by location, and what risk factors contribute to it. This study is non-pharmacological and collects data without adding any new treatments or procedures beyond usual care. Data will be collected at multiple centers during two separate two-week periods each year for five years. Participants include patients of all ages with chronic lung diseases who have had at least one respiratory sample collected within the past year. Clinical, demographic, and microbiological information will be gathered through questionnaires and medical records, all recorded in a secure electronic system. No additional tests or interventions outside routine clinical practice will be performed. Participants will provide informed consent before joining. Throughout the study, researchers will monitor the prevalence of antimicrobial resistance and analyze susceptibility patterns of key resistant pathogens, geographical differences, and risk factors for AMR by reviewing collected clinical and microbiological data. The study will last five years, with data collected periodically and securely maintained to better understand AMRs impact on chronic lung diseases.
Actively Recruiting
Researchers are evaluating the investigational drug omecamtiv mecarbil to see if it can reduce the risk of serious effects related to heart failure, such as hospitalization, heart transplantation, or death, in patients with symptomatic heart failure with severely reduced ejection fraction HFrEF. This Phase 3 trial compares the safety and effectiveness of omecamtiv mecarbil against a placebo in patients with this condition. Participants will be randomly assigned to receive either omecamtiv mecarbil or a placebo. Those in the omecamtiv mecarbil group will take oral tablets twice daily with doses adjusted based on drug levels in their blood 25, 37.5, or 50 mg. The treatment continues until at least 850 participants experience a heart failure event or cardiovascular death. This is a double-blind study, meaning neither participants nor study staff know who receives the drug or placebo. During the study, participants will be monitored up to about 3 years. Researchers will track occurrences of cardiovascular death, heart failure events, device implantations, heart transplants, and strokes. Participants will have regular visits and assessments to monitor their health and study outcomes. Safety and efficacy data will be collected until the study concludes when the required number of events has occurred.